HK1109350A1 - Solid forms of a chemokine receptor antagonist and methods of use thereof - Google Patents

Solid forms of a chemokine receptor antagonist and methods of use thereof

Info

Publication number
HK1109350A1
HK1109350A1 HK08103587.5A HK08103587A HK1109350A1 HK 1109350 A1 HK1109350 A1 HK 1109350A1 HK 08103587 A HK08103587 A HK 08103587A HK 1109350 A1 HK1109350 A1 HK 1109350A1
Authority
HK
Hong Kong
Prior art keywords
citrate salt
methods
crystalline
discussed
receptor antagonist
Prior art date
Application number
HK08103587.5A
Other languages
English (en)
Inventor
Carole Neves
Aurelia Chevalier
Pascal Billot
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of HK1109350A1 publication Critical patent/HK1109350A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/451Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
HK08103587.5A 2004-12-17 2008-04-01 Solid forms of a chemokine receptor antagonist and methods of use thereof HK1109350A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63721304P 2004-12-17 2004-12-17
PCT/US2005/045915 WO2006066200A2 (fr) 2004-12-17 2005-12-19 Formes solides d'un antagoniste du recepteur de la chimiokine et leurs methodes d'utilisation

Publications (1)

Publication Number Publication Date
HK1109350A1 true HK1109350A1 (en) 2008-06-06

Family

ID=36588631

Family Applications (1)

Application Number Title Priority Date Filing Date
HK08103587.5A HK1109350A1 (en) 2004-12-17 2008-04-01 Solid forms of a chemokine receptor antagonist and methods of use thereof

Country Status (10)

Country Link
US (2) US7960549B2 (fr)
EP (1) EP1841429B1 (fr)
JP (3) JP5308030B2 (fr)
CN (1) CN101119725B (fr)
AT (1) ATE553761T1 (fr)
AU (1) AU2005316340B2 (fr)
CA (1) CA2590157C (fr)
ES (1) ES2386029T3 (fr)
HK (1) HK1109350A1 (fr)
WO (1) WO2006066200A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023505116A (ja) * 2019-11-29 2023-02-08 ▲広▼▲東▼▲東▼▲陽▼光▲薬▼▲業▼有限公司 三環式含窒素化合物の結晶形及びその用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6509346B2 (en) 1998-01-21 2003-01-21 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
BR9910144A (pt) 1998-01-21 2002-04-02 Millennium Pharm Inc Antagonistas de receptores de quimiocinas e seu uso
US6433165B1 (en) * 1998-01-21 2002-08-13 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
US6613905B1 (en) * 1998-01-21 2003-09-02 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
WO2003045942A2 (fr) * 1998-09-04 2003-06-05 Millennium Pharmaceuticals, Inc. Antagonistes des recepteurs de la chimiokine et methodes d'utilisation de ces antagonistes
JP2002524461A (ja) 1998-09-04 2002-08-06 ミレニアム・ファーマシューティカルズ・インコーポレイテッド ケモカイン受容体アンタゴニストおよびその使用方法
US7271176B2 (en) * 1998-09-04 2007-09-18 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use thereof
US6503926B2 (en) 1998-09-04 2003-01-07 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
US20020169155A1 (en) * 1998-09-04 2002-11-14 Millennium Pharmaceuticals, Inc. Chemokine receptor anagonists and methods of use therefor
US6288083B1 (en) * 1998-09-04 2001-09-11 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
WO2001009137A1 (fr) 1999-07-28 2001-02-08 Millennium Pharmaceuticals, Inc. Antagonistes de recepteur de chemokine et procedes d'utilisation
US7541365B2 (en) 2001-11-21 2009-06-02 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
TWI291467B (en) * 2002-11-13 2007-12-21 Millennium Pharm Inc CCR1 antagonists and methods of use therefor

Also Published As

Publication number Publication date
US20120065223A1 (en) 2012-03-15
WO2006066200A3 (fr) 2007-01-25
JP2015057445A (ja) 2015-03-26
EP1841429B1 (fr) 2012-04-18
JP5308030B2 (ja) 2013-10-09
AU2005316340B2 (en) 2012-01-19
CA2590157A1 (fr) 2006-06-22
US8481737B2 (en) 2013-07-09
JP2012211197A (ja) 2012-11-01
CN101119725A (zh) 2008-02-06
JP2008524253A (ja) 2008-07-10
WO2006066200A2 (fr) 2006-06-22
ES2386029T3 (es) 2012-08-07
ATE553761T1 (de) 2012-05-15
CN101119725B (zh) 2013-04-17
EP1841429A2 (fr) 2007-10-10
US20070010545A1 (en) 2007-01-11
CA2590157C (fr) 2013-11-05
US7960549B2 (en) 2011-06-14
AU2005316340A1 (en) 2006-06-22

Similar Documents

Publication Publication Date Title
IL168056A0 (en) Selected cgrp antagonists, method for production and use thereof as medicament
GEP20063905B (en) Crystalline monohydrate, method for producing the same and the use thereof in the production of a medicament
HRP20130602T1 (en) 2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases
WO2005016261A3 (fr) Sels de pamoate d'aripiprazole et d'haloperidol
WO2005089753A3 (fr) Benzisoxazoles
PL1732917T3 (pl) Wybrani antagoniści CGRP, sposoby ich produkcji i ich zastosowanie jako leki
WO2003084539A3 (fr) Nouvelles compositions pharmaceutiques a base d'anticholinergiques et d'inhibiteurs de la kinase p38
WO2005107726A3 (fr) Procede pour le traitement de mal de dos
HUP0400333A3 (en) Crystalline anticholinergic, method for its production, and use thereof in the production of pharmaceutical composition
MY153198A (en) Inhibitors of protein aggregation
IL191311A (en) Transdermal therapeutic system and its use in the preparation of drugs for the prevention, treatment or delay of the progression of Alzheimer's disease, Parkinson's disease-related dementia and symptoms of traumatic brain injury
WO2005089486A3 (fr) Traitement anti-alcoolique
IL226313A0 (en) A method for producing gamma-carboxylated human prothrombin, isolated prothrombin produced by such a method, a pharmaceutical preparation including it and its use as drugs and for the production of drugs for the treatment of blood coagulation
WO2006047392A3 (fr) Synergie entre nicotine et opioides a des fins d'analgesie
MY154878A (en) Process for purifying staurosporine
HK1093729A1 (en) Substituted quinolones
WO2005089449A3 (fr) Methodes de traitement de l'alcoolisme
WO2004103283A3 (fr) Compositions comprenant un inhibiteur selectif de cyclooxygenase-2 et un stimulant de systeme nerveux central pour le traitement d'une lesion du systeme nerveux central
WO2004081043A3 (fr) Variants de baff et leurs methodes d'utilisation
WO2005039578A3 (fr) Utilisation de derive desoxynojirimycine ou de l'un de ses sels pharmaceutiquement admis
WO2004082584A3 (fr) Utilisation d'antagonistes du recepteur 5-ht2c pour traiter la schizophrenie
HK1109350A1 (en) Solid forms of a chemokine receptor antagonist and methods of use thereof
WO2006034106A3 (fr) Variantes baff et procedes associes
WO2007013962A3 (fr) Compositions de modafinil a action rapide et de courte duree et procedes d'utilisation de celles-ci
WO2005094798A3 (fr) Compositions pharmaceutiques a base d'anticholinergiques et d'antagonistes du recepteur ccr2

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20151219